Gene · 1308
Papers3,031
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 3,031
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Secretome of Bullous Pemphigoid IgG-Treated Keratinocytes Induces a Pro-Inflammatory Eosinophil Response. | Exp Dermatol | 2026 | 42100993 | PubTator, text mining | PubMed |
| Mesenchymal stem cell-derived exosomes promote scalp rejuvenation through type XVII collagen regulation via the miR-21-5p/DKK2/Wnt pathway. | Front Cell Dev Biol | 2026 | 42099389 | PubTator, text mining | PubMed |
| Corticosteroid-Sparing Control of Bullous Pemphigoid with Dupilumab and Tripterygium Glycosides: A Real-World Cohort with Longitudinal Transcriptomics. | J Inflamm Res | 2026 | 42094699 | PubTator, text mining | PubMed |
| Regulatory T cells in bullous pemphigoid: biological characteristics, dysfunction, and pathogenic roles. | Front Immunol | 2026 | 42094004 | PubTator, text mining | PubMed |
| Treg cells as potential therapeutic targets for bullous pemphigoid: A review. | J Dermatol Sci | 2026 | 42034524 | PubTator, text mining | PubMed |
| A case series of immune checkpoint inhibitor-induced bullous pemphigoid successfully treated with dupilumab and evidence for the BP180 midportion epitope as a preferential autoantigenic target. | Front Med (Lausanne) | 2026 | 41994451 | PubTator, text mining | PubMed |
| Gingival-Dominant Presentation of DPP-4 Inhibitor-Associated Bullous Pemphigoid: A Case Report. | Cureus | 2026 | 41988607 | PubTator, text mining | PubMed |
| Innovations in topical epidermolysis bullosa treatment: integrating advanced dressings, bioactive therapies and tissue-engineered skin. | Daru | 2026 | 41931158 | PubTator, text mining | PubMed |
| Evaluation of methotrexate and its influence on serum autoantibodies against BP180 in patients with bullous pemphigoid: a pilot study. | Acta Dermatovenerol Alp Pannonica Adriat | 2026 | 41915586 | PubTator, text mining | PubMed |
| Localized Bullous Pemphigoid Triggered by Surgical Trauma: A Case Highlighting the Koebner Phenomenon. | Cureus | 2026 | 41913877 | PubTator, text mining | PubMed |
| Acute Inflammation Drives Corneal Pathological Regeneration. | Invest Ophthalmol Vis Sci | 2026 | 41910526 | PubTator, text mining | PubMed |
| The role of serological investigations in the diagnosis of bullous pemphigoid: a retrospective study. | Ital J Dermatol Venerol | 2026 | 41891837 | PubTator, text mining | PubMed |
| Immune Checkpoint Inhibitor-Related Bullous Pemphigoid: Distinct Clinical and Immunological Profiles. | Exp Dermatol | 2026 | 41888879 | PubTator, text mining | PubMed |
| Refractory linear IgA dermatosis in childhood: a successful response to rituximab. | An Bras Dermatol | 2026 | 41875725 | PubTator, text mining | PubMed |
| Development of Intervertebral Disc Organoids through Directed Differentiation of Mesenchymal Stem Cells and Hierarchical 3D Printing. | ACS Nano | 2026 | 41849687 | PubTator, text mining | PubMed |
| Acute bullous iododerma with cryptococcoid neutrophilic dermatosis: A case series. | JAAD Case Rep | 2026 | 41808681 | PubTator, text mining | PubMed |
| Non-syndromic hyper-IgE in children: A practical approach. | World Allergy Organ J | 2026 | 41798765 | PubTator, text mining | PubMed |
| The dual role of BRD9 in cancer: Mechanistic insights and therapeutic prospects. | iScience | 2026 | 41797932 | PubTator, text mining | PubMed |
| Uncovering Clinically Relevant Breast Cancer Subtypes Biomarkers Using Integrative Bioinformatics and Machine Learning Approaches. | Biomarkers | 2026 | 41797509 | PubTator, text mining | PubMed |
| Vedolizumab-induced Bullous Pemphigoid: A Case Report with Serological Evidence and Mechanistic Insights. | Acta Derm Venereol | 2026 | 41772953 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1308/papers?page=3